Efeitos oculares associados ao padrão de uso e à dose de clorpromazina

Vaccaro, Fábio; Freda, Roberto; Marcon, Ítalo Mundialino; Seminotti, Norberto

doi:10.5935/0004-2749.19940058

Cited by 1 publication

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chlorpromazine was synthesized in France in 1950 by Charpentier, introduced as a clinical practice after 2 years by Delay and Deniker; frequent in psychoses treatment, especially schizophrenia. (1)(2)(3) Antipsychotics, like any drug, are capable of producing harmful effects on the body, along with the benefits that we seek when we medicate. (1) In 1958, adverse ocular effects were noticed in patients using chlorpromazine, (1) but they were only described by Greiner and Berry in 1964.…”

Section: Introductionmentioning

confidence: 99%

“…(1)(2)(3) Antipsychotics, like any drug, are capable of producing harmful effects on the body, along with the benefits that we seek when we medicate. (1) In 1958, adverse ocular effects were noticed in patients using chlorpromazine, (1) but they were only described by Greiner and Berry in 1964. (2,3) Since then, there have been several reports correlating this medicine with lens and corneal opacity.…”

Section: Introductionmentioning

confidence: 99%

“…(2,3) Since then, there have been several reports correlating this medicine with lens and corneal opacity. (1)(2)(3)(4)(5) In this paper, we report the case of a 65-year-old patient with ocular deposits due to long-term therapy with chlorpromazine.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Bilateral ocular deposit of chlorpromazine

Flügel¹,

Valle²,

Wasilewski³

2022

Revista Brasileira De Oftalmologia

View full text Add to dashboard Cite

Chlorpromazine is a medication widely used in psychiatry for the treatment of psychoses, especially schizophrenia. Since 1964, published articles have been correlating this medication with the appearance of ocular alterations. In this paper, we report the case of a 65-year-old patient with ocular effects due to long-term therapy with chlorpromazine. Biomicroscopy of both eyes presented diffuse granular brown deposits, most prominent at the deep stroma and corneal endothelium level. Also showed anterior subcapsular brown deposits with a stellate pattern in the lens. The total amount exceeds 2.000g (significant for the ocular alterations described) considering the patient's daily dosage of chlorpromazine of 300mg for ten years. After performing complete ophthalmic evaluation and discarding other causes for the ocular deposits, we diagnosed a secondary corneal deposit and cataract due to the use of chlorpromazine. This case reinforces the importance of periodic follow-up with an ophthalmologist for chlorpromazine users to trace ocular changes, heeding the exposure time and its dosage.

show abstract